| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| 靶点 |
SCD1 (Stearoyl-CoA Desaturase-1) (IC50: 8 nM for human SCD1 enzyme activity; IC50: 12 nM for mouse SCD1 enzyme activity) [1]
|
|---|---|
| 体外研究 (In Vitro) |
抑制SCD1酶活性
SCD1 inhibitor-4(1–100 nM)以剂量依赖方式抑制重组人及小鼠SCD1。在人SCD1 IC50(8 nM)和小鼠SCD1 IC50(12 nM)浓度下,酶活性降低50%;50 nM浓度下,抑制率分别达90%(人)和87%(小鼠),通过HPLC检测硬脂酰辅酶A向油酰辅酶A的转化实现[1] - 脂肪前体细胞抗增殖活性 在3T3-L1前脂肪细胞中,SCD1 inhibitor-4(0.1–10 μM)抑制细胞增殖,MTT法检测IC50为0.8 μM。2 μM浓度下,油红O染色显示脂肪细胞分化减少65%,GC-MS分析细胞脂肪酸显示油酸/硬脂酸(C18:1/C18:0)比例降低72%[1] - 肝细胞脂质代谢调节 在人 HepG2肝细胞中,SCD1 inhibitor-4(1–5 μM)以剂量依赖方式减少细胞内甘油三酯积累35%–58%(比色法)。qPCR检测显示,它下调生脂基因(SREBP-1c、FASN)mRNA表达42%–53%,并使脂肪酸氧化相关基因PPARα表达上调1.8倍(5 μM浓度)[1] |
| 体内研究 (In Vivo) |
SCD1抑制剂-4(1~30 mg/kg)的去饱和指数以剂量依赖性方式下降,在1 mg/kg剂量下下降55%,在10和30 mg/kg剂量下下降85% [1]。
db/db小鼠抗肥胖及降糖疗效 8–10周龄雄性db/db小鼠,每日口服SCD1 inhibitor-4(10、30 mg/kg)连续21天。30 mg/kg剂量组体重降低18%,摄食量减少12%。空腹血糖降低45%,糖化血红蛋白(HbA1c)水平降低32%(酶法检测)。血清甘油三酯和总胆固醇分别降低41%和35%[1] - 改善胰岛素敏感性 上述db/db小鼠模型中,30 mg/kg SCD1 inhibitor-4通过高胰岛素-正糖钳夹实验显示,葡萄糖输注率增加39%,表明胰岛素敏感性增强。肝脏甘油三酯含量降低52%(HPLC检测),油红O染色显示肝脂肪变性减轻[1] - 剂量依赖性脂质调节作用 10 mg/kg剂量下,SCD1 inhibitor-4使血清甘油三酯降低28%,肝脏甘油三酯降低31%;30 mg/kg剂量疗效更显著,与体外剂量依赖活性一致[1] |
| 酶活实验 |
SCD1酶活性实验
重组人/小鼠SCD1蛋白与SCD1 inhibitor-4(0.001–100 nM)在含硬脂酰辅酶A(底物)和NADPH(辅因子)的反应缓冲液中,37°C孵育45分钟。终止反应后,HPLC分离产物油酰辅酶A,通过峰面积定量计算酶活性抑制率和IC50值[1] - SCD1选择性实验 检测SCD1 inhibitor-4(1 μM)对其他脂肪酸去饱和酶(SCD2、FADS1、FADS2)的抑制活性,其对SCD1的选择性>100倍,对其他去饱和酶无显著抑制(<10%)[1] |
| 细胞实验 |
3T3-L1前脂肪细胞增殖与分化实验
3T3-L1细胞接种于96孔板(5×10³细胞/孔),过夜培养后加入SCD1 inhibitor-4(0.1–10 μM),孵育72小时后MTT法检测增殖。分化实验中,脂肪生成诱导期间(10天)加入抑制剂,油红O染色后检测吸光度,定量脂质积累[1] - HepG2肝细胞脂质代谢实验 HepG2细胞接种于6孔板(2×10⁵细胞/孔),培养24小时后加入SCD1 inhibitor-4(1–5 μM),孵育48小时。提取细胞内甘油三酯,比色法定量;提取总RNA,qPCR检测SREBP-1c、FASN和PPARα的mRNA表达[1] - 细胞脂肪酸组成分析 3T3-L1细胞经SCD1 inhibitor-4(2 μM)处理48小时后裂解,提取脂肪酸并甲基化,GC-MS分析。计算油酸(C18:1)与硬脂酸(C18:0)的比例,评估SCD1抑制效果[1] |
| 动物实验 |
db/db mouse metabolic disorder model
Male db/db mice (25–30 g, 8–10 weeks old) were acclimated for 7 days. SCD1 inhibitor-4 was suspended in 0.5% carboxymethylcellulose sodium (CMC-Na) and administered by oral gavage at 10 mg/kg or 30 mg/kg once daily for 21 days. Vehicle group received 0.5% CMC-Na. Body weight and food intake were recorded daily. Fasting blood glucose and HbA1c were measured on days 0, 7, 14, and 21. At study end, serum lipids (triglycerides, total cholesterol) were analyzed, and liver tissues were collected for triglyceride quantification and histological staining [1] - Hyperinsulinemic-euglycemic clamp assay After 14 days of treatment, db/db mice in the 30 mg/kg group underwent hyperinsulinemic-euglycemic clamp. Insulin was infused intravenously at a constant rate, and glucose was infused to maintain euglycemia. The glucose infusion rate was measured to assess insulin sensitivity [1] |
| 药代性质 (ADME/PK) |
Oral bioavailability:47% in mice (30 mg/kg oral dose) [1]
- Plasma half-life (t1/2):6.3 hours in mice (oral) [1] - Peak plasma concentration (Cmax):2.9 μM at 1 hour post-oral administration (30 mg/kg in mice) [1] - Plasma protein binding rate:91.5% (in vitro human plasma) [1] - Tissue distribution:Highest concentrations in liver (5.7 μM), adipose tissue (4.2 μM), and pancreas (3.8 μM) at 2 hours post-oral dose (30 mg/kg in mice) [1] |
| 毒性/毒理 (Toxicokinetics/TK) |
Acute toxicity:No mortality or obvious toxic signs (weight loss, lethargy, diarrhea) in mice after single oral dose up to 200 mg/kg [1]
- Chronic toxicity:In 28-day repeat-dose study (mice: 10, 30, 100 mg/kg oral daily), no significant changes in body weight, hematological parameters (WBC, RBC, platelets), or liver/kidney function markers (ALT, AST, BUN, creatinine) were observed. Histological examination of liver, kidney, heart, and adipose tissue showed no drug-related lesions [1] - No off-target toxicity:Due to high selectivity for SCD1, no adverse effects on other metabolic enzymes or organ function were reported [1] |
| 参考文献 | |
| 其他信息 |
Mechanism of action:SCD1 inhibitor-4 is a potent, selective inhibitor of SCD1, a key enzyme that catalyzes the conversion of saturated fatty acids (e.g., stearic acid) to monounsaturated fatty acids (e.g., oleic acid). By inhibiting SCD1, it reduces de novo lipogenesis, suppresses adipocyte differentiation and proliferation, enhances fatty acid oxidation, and improves insulin sensitivity, thereby exerting anti-obesity, hypoglycemic, and hypolipidemic effects [1]
- Therapeutic potential:Indicated for the treatment of metabolic disorders, including type 2 diabetes mellitus, obesity, and non-alcoholic fatty liver disease (NAFLD), by targeting SCD1-mediated lipid metabolism dysregulation [1] - Structural feature:The compound belongs to the N-benzylimidazole carboxamide class, with a structure optimized to bind the SCD1 active site, enabling high potency and selectivity [1] |
| 分子式 |
C17H16F3N5O
|
|---|---|
| 分子量 |
363.33705329895
|
| 精确质量 |
363.13
|
| 元素分析 |
C, 56.20; H, 4.44; F, 15.69; N, 19.28; O, 4.40
|
| CAS号 |
1295541-87-5
|
| PubChem CID |
51346908
|
| 外观&性状 |
White to off-white solid powder
|
| LogP |
2.7
|
| tPSA |
64.7
|
| 氢键供体(HBD)数目 |
1
|
| 氢键受体(HBA)数目 |
6
|
| 可旋转键数目(RBC) |
4
|
| 重原子数目 |
26
|
| 分子复杂度/Complexity |
503
|
| 定义原子立体中心数目 |
0
|
| InChi Key |
DUTKICDSXNUMBM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H16F3N5O/c1-11-15(16(26)22-14-6-7-24(2)23-14)21-10-25(11)9-12-4-3-5-13(8-12)17(18,19)20/h3-8,10H,9H2,1-2H3,(H,22,23,26)
|
| 化学名 |
5-methyl-N-(1-methylpyrazol-3-yl)-1-[[3-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide
|
| 别名 |
SCD1 inhibitor-4; DUN41875; DUN-41875; DUN 41875;
|
| HS Tariff Code |
2934.99.9001
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
DMSO : ~100 mg/mL (~275.22 mM)
|
|---|---|
| 溶解度 (体内实验) |
配方 1 中的溶解度: ≥ 2.5 mg/mL (6.88 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 配方 2 中的溶解度: ≥ 2.5 mg/mL (6.88 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 例如,若需制备1 mL的工作液,可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。 *20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。 View More
配方 3 中的溶解度: ≥ 2.5 mg/mL (6.88 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7522 mL | 13.7612 mL | 27.5224 mL | |
| 5 mM | 0.5504 mL | 2.7522 mL | 5.5045 mL | |
| 10 mM | 0.2752 mL | 1.3761 mL | 2.7522 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。